Professional Documents
Culture Documents
Farmakoterapija U Alzheimerovoj Bolesti MIMICA
Farmakoterapija U Alzheimerovoj Bolesti MIMICA
75
LITERATURA
1. Duraković Z. i sur. Farmakoterapija u gerijatriji. Zagreb: 7. Kales HC, Gitlin LN, Lyketsos CG. Assessment and
C.T. – Poslovne informacije, d.o.o.; 2011. American management of behavioral and psychological symp-
psychiatric association: Practice guidelines on the toms of dementia. BMJ. 2015 Mar;350:h369.
use of antipsychotics to treat agitation or psychosis
8. Kušan Jukić M, Mimica N. Frontotemporalna demen-
in patients with dementia. Arlington, USA 2016.
cija – ponašajni i psihički simptomi. U: Klepac N, Boro-
2. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. večki F, ur. Praktičan pristup bolesniku s demencijom
Long-term course and effectiveness of combination (Frontotemporalna demencija i Alzheimerova bolest).
therapy in Alzheimer disease. Alzheimer Dis Assoc Zagreb: Sveučilište u Zagrebu – Medicinski fakultet i
Disord. 2008 Jul-Sep;22(3):209-21. Medicinska naklada; 2016. str. 27-32.
3. Carson S, McDonagh MS, Peterson K. A systematic 9. Mimica N, Presečki P. How do we treat people with
review of the efficacy and safety of atypical antipsy- dementia in Croatia. Psychiatr Danub. 2010;22:363-6.
chotics in patients with psychological and behavi-
10. Mimica N, Presečki P. Side effects of approved anti-
oral symptoms of dementia. J Am Geriatr Soc. 2006
dementives. Psychiatr Danub. 2009 Mar; 21(1):108-13.
Feb;54(2):354-61.
11. Mimica N, Vitezić D. Alzheimer’s disease: guidelines
4. Devanand DP. Psychosis, agitation, and antipsyc-
for treatment and pharmacoeconomic impact. U:
hotic treatment in dementia. Am J Psychiatry. 2013
Vitezić D, Francetić I, ur. Second Croatian and First
Sep;170(9):957-60.
Adriatic Congress on Pharmacoeconomics and Out-
5. Duraković Z. i sur. Gerijatrija – medicina starije dobi. comes Research with International Participation; 2011
Zagreb: C.T. – Poslovne informacije, d.o.o.; 2007. Apr 6-Apr 9; Rovinj, Croatia. Pharmaca. 2010:(Sup.
1);48:43-4.
6. Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effe-
ctiveness of donepezil in the treatment of mild to 12. National Institute for Health and Clinical Excellen-
moderate Alzheimer’s disease: a UK evaluation using ce (NICE) Final Appraisal Determination. Donepezil,
discrete-event simulation. Pharmacoeconomics. galantamine, rivastigmine and memantine for the
2010;28(5):411-27. treatment of Alzheimer’s disease (review of NICE te-
chnology appraisal guidance 111). Issue date: January
2011. www.nice.org.uk/guidance/TA217.